Publication:
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

dc.contributor.coauthorEfe, Cumalı
dc.contributor.coauthorLammert, Craig
dc.contributor.coauthorTaşçılar, Koray
dc.contributor.coauthorDhanasekaran, Renumathy
dc.contributor.coauthorEbik, Berat
dc.contributor.coauthorHiguera-de la Tijera, Fatima
dc.contributor.coauthorÇalışkan, Ali R.
dc.contributor.coauthorPeralta, Mirta
dc.contributor.coauthorGerussi, Alessio
dc.contributor.coauthorMassoumi, Hatef
dc.contributor.coauthorCatana, Andreea M.
dc.contributor.coauthorPurnak, Tuğrul
dc.contributor.coauthorRigamonti, Cristina
dc.contributor.coauthorAldana, Andres J. G.
dc.contributor.coauthorKhakoo, Nidah
dc.contributor.coauthorNazal, Leyla
dc.contributor.coauthorFrager, Shalom
dc.contributor.coauthorDemir, Nurhan
dc.contributor.coauthorIrak, Kader
dc.contributor.coauthorMelekoğlu-Ellik, Zeynep
dc.contributor.coauthorKaçmaz, Hüseyin
dc.contributor.coauthorBalaban, Yasemin
dc.contributor.coauthorAtay, Kadri
dc.contributor.coauthorEren, Fatih
dc.contributor.coauthorAlvares-da-Silva, Mario R.
dc.contributor.coauthorCristoferi, Laura
dc.contributor.coauthorUrzua, Alvaro
dc.contributor.coauthorEskazan, Tugce
dc.contributor.coauthorMagro, Bianca
dc.contributor.coauthorSnijders, Romee
dc.contributor.coauthorBarutçu, Sezgin
dc.contributor.coauthorLytvyak, Ellina
dc.contributor.coauthorZazueta, Godolfino M.
dc.contributor.coauthorDemirezer-Bolat, Aylin
dc.contributor.coauthorAydın, Mesut
dc.contributor.coauthorHeurgue-Berlot, Alexandra
dc.contributor.coauthorDe Martin, Eleonora
dc.contributor.coauthorEkin, Nazım
dc.contributor.coauthorYıldırım, Sumeyra
dc.contributor.coauthorYavuz, Ahmet
dc.contributor.coauthorBıyık, Murat
dc.contributor.coauthorNarro, Graciela C.
dc.contributor.coauthorKıyıcı, Murat
dc.contributor.coauthorKahramanoğlu-Aksoy, Evrim
dc.contributor.coauthorVincent, Maria
dc.contributor.coauthorCarr, Rotonya M.
dc.contributor.coauthorGünsar, Fulya
dc.contributor.coauthorReyes, Eira C.
dc.contributor.coauthorHarputluoğlu, Murat
dc.contributor.coauthorAloman, Costica
dc.contributor.coauthorGatselis, Nikolaos K.
dc.contributor.coauthorÜstündağ, Yücel
dc.contributor.coauthorBrahm, Javier
dc.contributor.coauthorVargas, Nataly C. E.
dc.contributor.coauthorGüzelbulut, Fatih
dc.contributor.coauthorGarcia, Sandro R.
dc.contributor.coauthorAguirre, Jonathan
dc.contributor.coauthorAnders, Margarita
dc.contributor.coauthorRatusnu, Natalia
dc.contributor.coauthorHatemi, İbrahim
dc.contributor.coauthorMendizabal, Manuel
dc.contributor.coauthorFloreani, Annarosa
dc.contributor.coauthorFagiuoli, Stefano
dc.contributor.coauthorSilva, Marcelo
dc.contributor.coauthorİdilman, Ramazan
dc.contributor.coauthorSatapathy, Sanjaya K.
dc.contributor.coauthorSilveira, Marina
dc.contributor.coauthorDrenth, Joost P. H.
dc.contributor.coauthorDalekos, George N.
dc.contributor.coauthorAssis, David N.
dc.contributor.coauthorBjornsson, Einar
dc.contributor.coauthorBoyer, James L.
dc.contributor.coauthorYoshida, Eric M.
dc.contributor.coauthorInvernizzi, Pietro
dc.contributor.coauthorLevy, Cynthia
dc.contributor.coauthorMontano-Loza, Aldo J.
dc.contributor.coauthorSchiano, Thomas D.
dc.contributor.coauthorRidruejo, Ezequiel
dc.contributor.coauthorWahlin, Staffan
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkyıldız, Murat
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T13:45:58Z
dc.date.issued2022
dc.description.abstractBackground: we investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: we included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipItalian Ministry of University and Research (MIUR) Department of Excellence
dc.description.sponsorshipProject PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)
dc.description.versionPublisher version
dc.description.volume42
dc.identifier.doi10.1111/liv.15121
dc.identifier.eissn1478-3231
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03381
dc.identifier.issn1478-3223
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85121047570
dc.identifier.urihttps://hdl.handle.net/20.500.14288/3667
dc.identifier.wos729531700001
dc.keywordsAutoimmunity
dc.keywordsAzathioprine
dc.keywordsBudesonide
dc.keywordsLiver transplantation
dc.keywordsMercaptopurine
dc.keywordsSARS-CoV-2
dc.language.isoeng
dc.publisherWiley
dc.relation.grantnoNA
dc.relation.ispartofLiver International
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10168
dc.subjectGastroenterology and hepatology
dc.titleEffects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAkyıldız, Murat
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10168.pdf
Size:
491.04 KB
Format:
Adobe Portable Document Format